Merck & Co. Inc. is once again talking about biosimilars as a near-term business opportunity, after quietly taking a step back and recalibrating its strategy in the area in 2013.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?